Clinical Trial Update: Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

View source ↗

Summary

Clinical trial update for Pradaxa (dabigatran etexilate) focusing on prevention of venous thromboembolism after elective total hip or knee replacement; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthroplasty Replacement
• Venous Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Venous Thromboembolism, Arthroplasty, Replacement | Status: TERMINATED | Results posted: 2013-01-04